Welcome to our dedicated page for Rvltn Bioscnc SEC filings (Ticker: REVBW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revelation Biosciences, Inc. (warrants trading as REVBW) aggregates the company’s official regulatory disclosures, offering a structured view of its clinical, financial, and capital markets activities. Revelation’s filings include current reports on Form 8-K, proxy statements on Schedule 14A, and other documents that describe material events affecting both its common stock (REVB) and its redeemable warrants.
For investors analyzing this clinical-stage life sciences company, Form 8-K filings are particularly important. Recent 8-Ks have reported interim and topline clinical results, such as outcomes from the PRIME Phase 1b clinical study in chronic kidney disease patients and earlier viral challenge studies, as well as reverse stock split implementation, warrant terms, and changes to the rights of security holders. These filings also document how corporate actions, including reverse stock splits, result in proportionate adjustments to equity awards and to the REVBW warrants’ exercise ratios and prices.
Proxy statements (DEF 14A) provide detail on stockholder meetings and governance matters. A 2025 definitive proxy statement outlines a special meeting to approve the reservation and issuance of common shares under Class I Common Stock Warrants in excess of Nasdaq’s 20% exchange cap, and to authorize potential adjournment if additional proxies are needed. Other filings summarize annual meeting results, including votes on director elections, amendments to the 2021 Equity Incentive Plan, advisory votes on executive compensation, approval of reverse stock split authority, and warrant-related share issuances.
Quarterly and annual financial information is referenced through 8-Ks that furnish earnings press releases, where Revelation discusses operating expenses, net loss, and cash balances. These documents help investors understand the company’s cash runway and spending on clinical programs such as REVTx-99b, REVTx-99a, REVTx-200, and REVTx-300.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key terms, clinical outcomes, capital structure changes, and warrant mechanics. Users can quickly see how new filings affect REVB and REVBW, identify items related to reverse stock splits, warrant exchange caps, or stockholder approvals, and then drill into the original EDGAR documents when they need full legal and financial detail.
Revelation Biosciences reported 2025 results showing lower losses, a stronger balance sheet, and progress with its Gemini inflammation program. Net loss for 2025 was $8.9 million, improved from $15.0 million in 2024, as operating cash burn decreased.
Net cash used for operating activities fell to $8.3 million from $18.3 million, while cash and cash equivalents rose to $10.7 million at December 31, 2025 from $6.5 million a year earlier, helped by a May 2025 public offering and a September 2025 warrant inducement.
The company expects its cash to fund operations into the first quarter of 2027. It highlighted positive PRIME study results in late-stage chronic kidney disease, an FDA agreement on a single adaptive Phase 2/3 study of Gemini for acute kidney injury, and planned presentation of Gemini data at a major nephrology conference.
Revelation Biosciences reported 2025 results showing lower losses, a stronger balance sheet, and progress with its Gemini inflammation program. Net loss for 2025 was $8.9 million, improved from $15.0 million in 2024, as operating cash burn decreased.
Net cash used for operating activities fell to $8.3 million from $18.3 million, while cash and cash equivalents rose to $10.7 million at December 31, 2025 from $6.5 million a year earlier, helped by a May 2025 public offering and a September 2025 warrant inducement.
The company expects its cash to fund operations into the first quarter of 2027. It highlighted positive PRIME study results in late-stage chronic kidney disease, an FDA agreement on a single adaptive Phase 2/3 study of Gemini for acute kidney injury, and planned presentation of Gemini data at a major nephrology conference.
Revelation Biosciences, Inc. files its annual report as a clinical‑stage biotech focused on kidney disease, built around its Gemini immunomodulatory platform. Gemini is being developed as GEM‑AKI for acute kidney injury and GEM‑CKD for chronic kidney disease, both driven by dysregulated inflammation.
The company reports extensive preclinical and early clinical data showing Gemini’s effects on inflammatory markers, kidney injury models, and immune rebalancing in CKD patients. Revelation has FDA agreement on a single Phase 2/3 adaptive study in AKI, targeting a composite endpoint of death and/or dialysis, and plans 2026 infrastructure build‑out to start this trial.
The report highlights significant business risks: ongoing net losses, a going concern qualification, a need for additional funding, dependence on a single PHAD supplier, intense competition, and reliance on continued Nasdaq listing. Multiple reverse stock splits and a small equity base of 3,720,420 common shares as of February 23, 2026 underscore financing and volatility concerns.
Revelation Biosciences, Inc. files its annual report as a clinical‑stage biotech focused on kidney disease, built around its Gemini immunomodulatory platform. Gemini is being developed as GEM‑AKI for acute kidney injury and GEM‑CKD for chronic kidney disease, both driven by dysregulated inflammation.
The company reports extensive preclinical and early clinical data showing Gemini’s effects on inflammatory markers, kidney injury models, and immune rebalancing in CKD patients. Revelation has FDA agreement on a single Phase 2/3 adaptive study in AKI, targeting a composite endpoint of death and/or dialysis, and plans 2026 infrastructure build‑out to start this trial.
The report highlights significant business risks: ongoing net losses, a going concern qualification, a need for additional funding, dependence on a single PHAD supplier, intense competition, and reliance on continued Nasdaq listing. Multiple reverse stock splits and a small equity base of 3,720,420 common shares as of February 23, 2026 underscore financing and volatility concerns.
Revelation Biosciences Schedule 13G/A shows Armistice Capital, LLC and Steven Boyd report 288,332 shares beneficially owned, representing 4.99% of common stock. The filing states the Reporting Persons hold shared voting and shared dispositive power over 288,332 shares and that Armistice is investment manager to the direct holder, Armistice Capital Master Fund Ltd.
The filing attributes voting and investment power to Armistice Capital under an Investment Management Agreement and notes the Master Fund retains legal title while disclaiming beneficial ownership due to its inability to vote or dispose of the shares.
Revelation Biosciences Schedule 13G/A shows Armistice Capital, LLC and Steven Boyd report 288,332 shares beneficially owned, representing 4.99% of common stock. The filing states the Reporting Persons hold shared voting and shared dispositive power over 288,332 shares and that Armistice is investment manager to the direct holder, Armistice Capital Master Fund Ltd.
The filing attributes voting and investment power to Armistice Capital under an Investment Management Agreement and notes the Master Fund retains legal title while disclaiming beneficial ownership due to its inability to vote or dispose of the shares.
Revelation Biosciences, Inc. is calling a virtual special stockholder meeting on March 18, 2026 to vote on a key financing-related proposal. The main item is approval for the reservation and issuance of common shares underlying newly issued Class J Common Stock Warrants, where exercises could exceed 20% of shares outstanding and trigger Nasdaq’s Rule 5635(d) share issuance cap.
These Class J warrants were issued on January 23, 2026 in a warrant inducement deal tied to the exercise of 2,136,251 Class I warrants at an exercise price of $8.80 per share and are exercisable for five years at an exercise price of $3.44 per share. As of January 26, 2026, there were 10,492,469 shares of common stock outstanding, each with one vote. A second proposal would allow adjournment of the meeting if there are not enough proxies to approve the warrant share issuance. The board unanimously recommends voting in favor of both proposals.
Revelation Biosciences, Inc. is calling a virtual special stockholder meeting on March 18, 2026 to vote on a key financing-related proposal. The main item is approval for the reservation and issuance of common shares underlying newly issued Class J Common Stock Warrants, where exercises could exceed 20% of shares outstanding and trigger Nasdaq’s Rule 5635(d) share issuance cap.
These Class J warrants were issued on January 23, 2026 in a warrant inducement deal tied to the exercise of 2,136,251 Class I warrants at an exercise price of $8.80 per share and are exercisable for five years at an exercise price of $3.44 per share. As of January 26, 2026, there were 10,492,469 shares of common stock outstanding, each with one vote. A second proposal would allow adjournment of the meeting if there are not enough proxies to approve the warrant share issuance. The board unanimously recommends voting in favor of both proposals.
Revelation Biosciences director Jess Roper reported a mandatory tax-related share sale. On February 3, 2026, the issuer sold 1,591 shares of common stock on Roper’s behalf to cover tax obligations arising from vested restricted stock awards. The weighted average sale price was $1.85 per share, with individual trades ranging from $1.84 to $1.88. After this transaction, Roper directly beneficially owned 12,828 common shares. All share amounts reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.
Revelation Biosciences director Jess Roper reported a mandatory tax-related share sale. On February 3, 2026, the issuer sold 1,591 shares of common stock on Roper’s behalf to cover tax obligations arising from vested restricted stock awards. The weighted average sale price was $1.85 per share, with individual trades ranging from $1.84 to $1.88. After this transaction, Roper directly beneficially owned 12,828 common shares. All share amounts reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.
Revelation Biosciences director Lakhmir S. Chawla had 2,261 common shares sold on February 3, 2026 to cover taxes on vesting restricted stock. The issuer sold the shares on the director’s behalf at a weighted average price of $1.85 per share.
After this mandatory tax-withholding transaction, Chawla beneficially owned 12,158 common shares directly. All share figures reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.
Revelation Biosciences director Lakhmir S. Chawla had 2,261 common shares sold on February 3, 2026 to cover taxes on vesting restricted stock. The issuer sold the shares on the director’s behalf at a weighted average price of $1.85 per share.
After this mandatory tax-withholding transaction, Chawla beneficially owned 12,158 common shares directly. All share figures reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.
Revelation Biosciences, Inc. Chief Financial Officer Chester S. Zygmont III reported a mandatory sale of 13,100 shares of common stock on February 4, 2026. The issuer sold these shares on his behalf solely to cover tax withholding from vesting restricted stock awards.
The weighted average sale price was $1.65 per share, with individual trades ranging from $1.63 to $1.66. All share figures reflect a 1-for-4 reverse stock split effective January 28, 2026. After the transaction, 105,348 shares are held indirectly by The Zygmont Family Trust and 2 shares are held indirectly by Czeslaw Capital Fund, LLC, both entities associated with the CFO.
Revelation Biosciences, Inc. Chief Financial Officer Chester S. Zygmont III reported a mandatory sale of 13,100 shares of common stock on February 4, 2026. The issuer sold these shares on his behalf solely to cover tax withholding from vesting restricted stock awards.
The weighted average sale price was $1.65 per share, with individual trades ranging from $1.63 to $1.66. All share figures reflect a 1-for-4 reverse stock split effective January 28, 2026. After the transaction, 105,348 shares are held indirectly by The Zygmont Family Trust and 2 shares are held indirectly by Czeslaw Capital Fund, LLC, both entities associated with the CFO.
Revelation Biosciences, Inc. has filed an S-3 registration statement covering the resale of up to 4,272,500 shares of common stock. These shares are issuable upon exercise of Class J common stock warrants granted under a January 23, 2026 inducement letter.
The Class J warrants are exercisable after stockholder approval for five years at an exercise price of $3.44 per share. Revelation is not selling shares in this offering and will not receive proceeds from resales, but could receive up to approximately $14,697,400 if all warrants are exercised in cash.
The filing follows a private warrant exercise in which two holders immediately exercised 2,136,251 Class I warrants at $3.44, providing gross proceeds of $7,348,699. Shares outstanding were 2,623,118 as of January 26, 2026 and would be 6,895,618 assuming full warrant exercise. Class J warrant exercises are limited by 4.99% and 9.99% beneficial ownership caps.
Revelation Biosciences, Inc. has filed an S-3 registration statement covering the resale of up to 4,272,500 shares of common stock. These shares are issuable upon exercise of Class J common stock warrants granted under a January 23, 2026 inducement letter.
The Class J warrants are exercisable after stockholder approval for five years at an exercise price of $3.44 per share. Revelation is not selling shares in this offering and will not receive proceeds from resales, but could receive up to approximately $14,697,400 if all warrants are exercised in cash.
The filing follows a private warrant exercise in which two holders immediately exercised 2,136,251 Class I warrants at $3.44, providing gross proceeds of $7,348,699. Shares outstanding were 2,623,118 as of January 26, 2026 and would be 6,895,618 assuming full warrant exercise. Class J warrant exercises are limited by 4.99% and 9.99% beneficial ownership caps.
Revelation Biosciences, Inc. is the subject of a Schedule 13G reporting that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together beneficially own 605,702 shares of its common stock, representing 9.56% of the class as of the event date of 12/31/2025. The filing shows these shares are held with shared voting and dispositive power and no sole voting or dispositive power. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Revelation Biosciences.
Revelation Biosciences, Inc. is the subject of a Schedule 13G reporting that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together beneficially own 605,702 shares of its common stock, representing 9.56% of the class as of the event date of 12/31/2025. The filing shows these shares are held with shared voting and dispositive power and no sole voting or dispositive power. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Revelation Biosciences.
Revelation Biosciences, Inc. is soliciting shareholder votes at a Special Meeting to approve a proposal limiting conversions under certain warrants issued September 11, 2025, which could trigger Nasdaq’s 20% share issuance cap. The proposal would constrain issuances under those warrants to avoid exceeding the Exchange Cap. On the record date there were 2,339,306 shares outstanding, with each share entitled to one vote. The warrant holders—Sabby Volatility Warrant Master Fund, Ltd., Armistice Capital Master Fund Ltd. and Hudson Bay Master Fund Ltd.—are interested parties but have agreed to vote their shares in the same proportion as non-interested stockholders. The board recommends voting FOR both Proposal 1 (the conversion limitation) and Proposal 2 (adjournment if insufficient proxies). Shareholders may vote by returning the proxy card or attend and vote telephonically; beneficial owners must obtain a broker or nominee proxy to vote.